Dr Jacoline Bouvy is technical director at NICE – the National Institute for Health and Care Excellence in the UK. Jacoline signs off and quality assures work across all services offered by the scientific advice team. She chairs national and parallel scientific advice meetings with medical device and pharmaceutical companies. She also works on the joint NICE, NHS England and Department of Health and Social Care (DHSC) project that’s developing new payment models for antimicrobials. And she is chief analyst for NICE on the DHSC’s health and care appraisal working group.Previously Jacoline worked in our science policy and research team. She led our work on a number of pan-European research projects, including the European Health Data and Evidence Network, health technology assessment of histology independent cancer drugs, and the use of patient preference studies in health technology assessment.
Before joining NICE, Jacoline worked at the European Medicines Agency. Prior to this she held postdoctoral positions in the Netherlands, at Erasmus University Rotterdam and Utrecht University. She has a PhD from Utrecht University and an MSc in Health Economics from Erasmus University.
Ihsane Hmamouchi @epirheum is a rheumatologist at Temara Hospital in Rabat Morocco and Associate Professor at Laboratory of Biostatistics, Epidemiology and Clinical Research (LERC) at Mohammed V University Rabat. She is founder of EpiRheum.com As a student at Rabat’s Faculty of Medicine, Ihsane quickly found herself looking for a subject that would satisfy both her creativity and curiosity. Her interest in clinical research led her to undertake a PhD in clinical epidemiology. She was thus able to combine these two fields of predilection, rheumatology and clinical epidemiology. She is very enthusiastic about continually expanding her knowledge and critical thinking in the field of clinical research and all fields of rheumatology. Besides, she enjoys facilitating future collaborations and benchmarking her networking.
Keywords: spondyloarthritis, osteoporosis, imaging, education, clinical epidemiology, outcomes assessment, quality of life, social media.
Click here for links to her publications.
Professor Ole Petter Ottersen is President of the Karolinska Institute, Stockholm, Sweden where he took office on August 1, 2017 after having served eight years (2009-2017) as rector (President) of the University of Oslo (UiO). From 2002 to 2009 I was Director of Centre for Molecular Biology and Neuroscience – one of Norway’s Centres of Excellence. He served as Dean of Research at UiO’s Faculty of Medicine (2000-2002) and as Head of the UiO’s Department of Anatomy (1997-1999). In his period as rector, he led the Norwegian Association of Higher Education Institutions (2013- 2015) and NUS-Det nordiska universitetssamarbetet (2013-2015). He headed one of UiO’s interdisciplinary initiatives (EMBIO; now UiO:Life Science) and one of the major national programmes of the Norwegian Research Council (FUGE: Functional Genomics in Norway). He coordinated two projects under the EU Framework Programme and one of the first three Nordic Centres of Excellence in Molecular Medicine, funded by NordForsk. He has taught medical students since 1976.
From 2006 to 2009 he served as Chief Editor of Neuroscience – the official journal of the International brain research organization (IBRO). H has been engaged in a number of international institutional evaluations and served as panel leader in the European research Council (ERC Advanced Grants) from the start to 2012. He was Founding Chair (2016-2017) of a newly established European university network (the Guild of Research Intensive Universities) and chaired the Lancet Commission that studied the political determinants of global health inequalities (The Lancet-University of Oslo Commission on Global Governance for Health). He has served at a number of boards, including the Board of the Oslo University Hospital (2012-2017) and chaired Samarbeidsorganet (Joint Council) of the regional health authority (Helse Sør-Øst) and University of Oslo, alternating with the Director of Helse Sør-Øst. He has led several prize award committees, and is the current Chair of the Kavli Prize Committee in Neuroscience and of the Thon Foundation Advisory Board. At the Nordic level he has been board Member of Wallenberg Consortium North (2002-2006), Member of the Scientific Advisory Board of Lundbeck Foundation (2007-2013), and Member of the board of Nordforsk (2013-2016).
Ken Redekop PhD @dontwaitforit is Editor-in-Chief for the FPM journal Health Policy and Technology and Honorary Secretary of the FPM. He is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.
Bettina Ryll is the current chair of the ESMO Patient Advocates Working Group (PAWG). Dr. Ryll holds a medical degree from the Free University of Berlin, Germany and a PhD in Biomedical Sciences from University College London, UK. After losing her husband to melanoma, she founded the Melanoma Patient Network Europe and developed a special interest in patient-centric clinical research, in particular, innovative trial designs and novel drug development concepts, such as MAPPS (medicines’ adaptive pathways to patients), previously known as Adaptive Licensing. Lately, her focus has moved to sustainable healthcare models ensuring access to innovative therapies for cancer patients and incentives for sustainable innovation.
Dr. Ryll is involved in numerous initiatives promoting evidence-based advocacy. She is fascinated by the enormous potential and capacity of patient networks to both educate and support patients as well as to capture data at the primary data source – the patients themselves – and to generate evidence at a granular level non-accessible to outsiders. Since 2015, Dr. Ryll has chaired the ESMO Patient Advocates Working Group, the first time this position has been held by a non-oncologist. The PAWG is responsible for the Patient Advocacy Track at the annual ESMO meeting, organises workshops of interest to the wider advocacy and medical community and has an advisory function for ESMO activities. She has also been member of the ESMO Quality of Care Task Force since 2015.
Duane Schulthess is Managing Director of Vital Transformation, a consultancy focused on quantifying and defining innovation and change in the health-care sector. He regularly works with regulators, multi-national corporations, governments, and stakeholder groups, clarifying the impact of health policy changes and technological innovations. He has been a speaker at many leading international conferences including BIO, the European Health Forum Gastein, DIA, and The Basel Biozentrum. Mr. Schulthess’ 2019 BMJ publication titled “Are CAR-T therapies living up to their hype?” is considered a ground-breaking analysis in the field of real-world evidence, and has been cited in presentations by the European Medicines Agency and EUnetHTA.
Previously, Duane was the EMEA Head of Corporate Development of The Wall Street Journal, and was the Commercial Director of Science|Business. He has a BA Magna Cum Laude from the University of the Pacific where he was also nominated to the Phi Kappa Phi honour society, and an MBA with Distinction from KU Leuven’s Vlerick Management School. From 1988-91, he was a recipient of a Leverhulme Trust Fellowship at the Royal Academy of Music in London where he won several music performance prizes and competitions while also studying economics on an international exchange programme at Regent’s College. He was recently appointed as a senior associate of the UK’s Royal Society of Medicine.
Professor Donald Singer @HealthMed is President of the FPM. He is a Clinical Pharmacologist interested in new approaches to personalising medicine and in public understanding of health and drugs. He is a member of the panel of experts of the European Medicines Agency has been a member since 2013 of the Healthcare Professionals’ Working Party of the European Medicines Agency for which he has been involved in projects on minimizing risk from medicines. International consultancy includes advice on clinical pharmacology and safety systems for medicines as a Yale School of Medicine Faculty member within the 7 year Human Resources for Health US-AID and CDC supported programme in Rwanda. Singer is President of the UK Fellowship of Postgraduate Medicine, which publishes the Postgraduate Medical Journal (founded 1925) and Health Policy and Technology (founded 2012). He is a former Secretary of the European Association of Clinical Pharmacology and Therapeutics which supports scientific and educational exchange for over 4000 clinical pharmacologists from 34 countries. He was previously also a member of the Council of the British Pharmacological Society and Panel Member of the NIHR Health Technology Assessment Programme.